Meghan M. Heberton

Jun 10, 2024 | dermatologytimes.com | Meghan M. Heberton |Heidi Anne Duerr

“Immunotherapy as a whole has changed cancer outcomes for patients,” Meghan Heberton, MD, assistant professor of dermatology at University of Texas Southwestern Medical Center, told Dermatology Times in an exclusive interview at the 2024 Annual Society of Dermatology Physician Assistants Annual Summer Dermatology Conference in San Diego, California. “Cutaneous adverse events from immunotherapy are one of the primary side effects seen from those therapies.

Jun 4, 2024 | dialnet.unirioja.es | Sophia N. Wix |M Phil |Ariel Brown |Meghan M. Heberton

Clinical Features and Outcomes of Black Patients With MelanomaAutores: Sophia N. Wix, M Phil, Ariel B. Brown, Meghan Heberton, Adewole S. Adamson, Jennifer G. GillLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 160, Nº. 3, 2024, págs. 328-333Idioma: inglésTexto completo no disponible (Saber más ...)ResumenMelanoma in Black individuals has an annual incidence of approximately 1 in 100 000 people.

Jan 24, 2024 | jamanetwork.com | Sophia N. Wix |Ariel Brown |Meghan M. Heberton |Jennifer Gill

Key PointsQuestion  What characteristics are associated with melanoma development and poor outcomes in Black patients? Findings  In this single-institution case series of 48 Black patients with melanoma, 75% of cutaneous melanomas occurred on acral skin; nonacral cutaneous melanomas were seen more often in patients who were immunocompromised and/or had a personal history of other cancers.